Related Experiment Video
Updated: Jun 28, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
A role for the p53 pathway in the pathology of meningiomas with NF2 loss
ZeNan Chang1, Chin-Lin Guo, Iris Ahronowitz
1Division of Biology, California Institute of Technology, Pasadena, CA 91125, USA.
Abstract:
The neurofibromatosis 2 locus (NF2) is inactivated through mutation and loss of heterozygosity (LOH) in 40-65% of all sporadic meningiomas, while the role of the p53 tumor suppression pathway in meningioma initiation and progression is still unclear. This study aims to determine if a p53 codon 72 arginine-to-proline polymorphism, found to be correlated with cancer development and cancer patient survival in other tumors, is associated with sporadic meningioma initiation or progression. We investigated Pro72 incidence in a cohort of 92 sporadic meningiomas and analyzed its association with histological grade (WHO classification) and with NF2 LOH (determined using polymorphic microsatellite markers on 22q). The Pro72 allele was not found to be selected for in the cohort. However, in the subgroup of meningiomas with NF2 LOH and carrying Pro72, 50.0% had high grade tumors (WHO grades II and III) compared to only 14.3% of those without NF2 LOH (OR = 6.0, CI = 1.56-23.11, P = 0.012). The significant association occurred only when considering subgroups of meningiomas with or without NF2 LOH, suggesting that not including NF2 status when analyzing study cohorts may explain the variability seen in the literature where all meningiomas were grouped together. Our data suggests a role for the p53 pathway in the progression of meningiomas in which NF2 is inactivated, and highlights the importance of accounting for NF2 LOH in future studies of meningiomas and the p53 pathway.
Insights
The p53 codon 72 polymorphism is linked to higher-grade meningiomas, but only when the neurofibromatosis 2 (NF2) gene is also lost. This suggests p53 influences tumor progression in NF2-inactivated meningiomas.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Neurofibromatosis 2 (NF2) gene inactivation occurs in 40-65% of sporadic meningiomas.
- The role of the p53 tumor suppressor pathway in meningioma development is not fully understood.
- A p53 codon 72 polymorphism (arginine-to-proline) has been linked to cancer outcomes in other tumor types.
Purpose of the Study:
- To investigate the association of the p53 codon 72 arginine-to-proline polymorphism with sporadic meningioma initiation and progression.
- To determine if this polymorphism correlates with tumor grade or NF2 loss of heterozygosity (LOH).
Main Methods:
- Analysis of p53 codon 72 polymorphism incidence in 92 sporadic meningioma samples.
- Assessment of tumor histological grade (WHO classification).
- Determination of NF2 LOH using polymorphic microsatellite markers on chromosome 22q.
Main Results:
- The Pro72 allele was not found to be selected for in the overall cohort.
- In meningiomas with NF2 LOH, carriers of Pro72 showed a significantly higher incidence of high-grade tumors (50.0%) compared to those without NF2 LOH (14.3%).
- The association between Pro72 and high-grade tumors was only significant when NF2 LOH status was considered (OR = 6.0, P = 0.012).
Conclusions:
- The p53 codon 72 polymorphism may play a role in the progression of meningiomas with concurrent NF2 inactivation.
- Accounting for NF2 LOH status is crucial for future studies investigating the p53 pathway in meningiomas.
- This finding highlights the complex interplay between genetic alterations in meningioma pathogenesis.
More Related Videos
09:33Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
Related Concept Videos
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Negative Regulator Molecules
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
DNA Damage Can Stall the Cell Cycle